Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 25;12(9):e0185566.
doi: 10.1371/journal.pone.0185566. eCollection 2017.

Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro

Affiliations

Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro

Daphne Gschwantler-Kaulich et al. PLoS One. .

Abstract

Background: Zoledronic acid (ZA) has antiresorptive effects and protects from bone metastasis in women with early breast cancer. In addition, in postmenopausal women with endocrine responsive breast cancer ZA prolongs DFS. The exact mechanism is still unclear. We have therefore investigated the effect of increasing concentrations of ZA in breast cancer cell lines in the absence or presence of estradiol to mimic the hormonal environment in vitro.

Materials and methods: Using assays for cell proliferation (EZ4U, BrdU) and cell death (Annexin/PI), we have analyzed the dose-dependent antiproliferative and pro-apoptotic effects of ZA in two hormone sensitive cell lines (MCF-7 and T47D) and a hormone insensitive, triple negative cell line (MDA-MB-231) in the presence of 0, 1 and 10 nM estradiol.

Results: In the absence of estradiol, ZA exerts dose-dependent antiproliferative and pro-apoptotic antitumor effects in both, hormone sensitive (MCF-7, T47D) and -insensitive (MDA-MB-231) breast cancer cell lines (p<0.0001). In the presence of estradiol, the antitumoral effect of ZA was significantly decreased only in the hormone sensitive MCF-7 and T47D cell lines (p = 0.0008 and p = 0.0008, respectively).

Conclusion: We have demonstrated that estradiol impairs the antiproliferative and proapoptotic effect of ZA in hormone sensitive, but not in hormone insensitive breast cancer cell lines. Our findings provide a possible explanation for the differential effect of ZA on DFS in pre- and postmenopausal patients with hormone sensitive early breast cancer, which has been demonstrated clinically. We further hypothesize that endocrine insensitive tumors such as triple negative breast cancer (TNBC) should benefit from ZA irrespective of their menopausal status.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: We have the following interests: Mario Mairhofer is employed by Center for Advanced Bioanalysis GmbH LTD. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Figures

Fig 1
Fig 1. Proliferative effect of estradiol.
Proliferative effect of 0, 1 and 10nM estradiol on the three cell lines MCF-7 (black), T74D (grey) and MDA-MD-231 (white) in the absence of ZA (EZ4U). Abbreviations: OD = optical density.
Fig 2
Fig 2. Dose-dependent antiproliferative effect of ZA.
Dose-dependent antiproliferative effect of ZA on the three cell lines in the absence (A) and the presence (B) of 1nM estradiol (EZ4U). Abbreviations: OD = optical density.
Fig 3
Fig 3. Antiproliferative effect of ZA in the absence or presence of different concentrations of estradiol.
Antiproliferative effect of rising concentrations of ZA (0, 6.25 and 12.5μM) in the three cell lines MCF-7 (A), T47D (B) and MDA-MB-231 (C) in the absence (black bars) or the presence of 1nM (grey bars) and 10nM (white bars) estradiol (EZ4U).
Fig 4
Fig 4. Effect of ZA on DNA synthesis.
Effect of rising concentrations of ZA on DNA synthesis in the three cell lines MCF-7 (A), T74D (B) and MDA-MB-231 (C) in the absence (blue bars) and the presence (red bars) of 1nM estradiol (BrdU).
Fig 5
Fig 5. Cell cycle analysis by DNA content.
Dose-dependent pro-apoptotic effect of ZA in the three cell lines MCF-7 (A), T47D (B), MDA-MB-231 (C) in the absence or the presence of 1nM estradiol shown by the Sub-G1-Peak.
Fig 6
Fig 6. Pro-apoptotic effect of ZA measured by Annexin/PI staining.
Pro-apoptotic effect of rising concentrations of ZA in the three cell lines MCF-7 (A), T47D (B), MDA-MB-231 (C) in the absence or the presence of 1nM estradiol measured by AnnexinV/PI staining.

Similar articles

Cited by

References

    1. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717. doi: 10.1016/S0140-6736(05)66544-0 - DOI - PubMed
    1. Clezardin P. Potential anticancer properties of bisphosphonates: insights from preclinical studies. Anticancer Agents Med Chem 2012;12:102–113. - PubMed
    1. Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011;22:2546–2555. doi: 10.1093/annonc/mdr017 - DOI - PubMed
    1. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, et al. Final 5-year results of z-fast trial: adjuvant ZA maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012;118:1192–1201. doi: 10.1002/cncr.26313 - DOI - PubMed
    1. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. ZA (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (zo-fast study): final 60-month results. Ann Oncol 2013;24:398–405. doi: 10.1093/annonc/mds277 - DOI - PubMed

MeSH terms